We recently compiled a list of the 10 Firms Defy Market Pessimism. In this article, we are going to take a look at where Neuphoria Therapeutics Inc. (NASDAQ:NEUP) stands against the other firms.
Ten companies finished firmer on Friday, bucking an overall market pessimism, over a series of catalysts sparking buying appetite.
Wall Street’s main indices all finished in the red territory, with the Dow Jones down by 0.32 percent, the S&P 500 dropped 0.29 percent, and the Nasdaq down 0.50 percent.
In this article, let’s take a look at which companies defied broader market pessimism and explore the reasons behind their growth.
Friday’s top advancers only considered the stocks with at least $2 billion in market capitalization and $5 million in daily trading volume.
A close up of a lab technician in a protective suit, working with cells in a petri dish to develop innovative therapeutics for immune-related diseases.
Neuphoria Therapeutics Inc. (NASDAQ:NEUP)
Neuphoria Therapeutics Inc. saw its share prices jump by 25.79 percent on Friday to end at $4.39 apiece as investors resorted to bargain-hunting to take advantage of the company’s cheap valuations, as it nears a 52-week low.
In the news, Neuphoria Therapeutics recently regained compliance with the Nasdaq’s minimum bid price requirement, having flagged for falling below the requirement.
In July 2024, the company received a deficiency letter from Nasdaq due to its American Depositary Shares not meeting the $1 minimum bid price over a 30-day period.
The issue is now resolved and the matter is considered closed—a development significant for Neuphoria Therapeutics as falling below the minimum requirement threatens itself from maintaining a position on the stock exchange.
READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap
This article is originally published at Insider Monkey.